Adrian Wiestner, MD, PhD, Discusses the Clinical and Economic Outcomes Associated With the Use of Targeted Kinase Inhibitors in CLL

Adrian Wiestner, MD, PhD, Investigator, Laboratory of Lymphoid Malignancies, National Heart Lung and Blood Institute, discusses the patient outcomes that clinical trials have demonstrated regarding the use of targeted kinase inhibitors for the management of chronic lymphocytic leukemia (CLL). He notes that, currently, there may not be enough information to develop a comprehensive understanding of the economic implications, but offers that, perhaps looking at chronic myelogenous leukemia (CML) will provide some important relative insight.

This video was taken on Monday, December 10, at the American Society of Hematology's 54th Annual Meeting in Atlanta, GA.